Overview
The Right Drugs at the Right Time: The Cost-Savings Case for Tying PAH Formulary Protocols to Best Available Clinical Evidence
Satellite Symposium during AMCP Nexus
Registration is closed for this activity.
Our expert faculty, comprised of a managed care pharmacist and pulmonologist specializing in PAH, will review recent guideline recommendations and strategies for selecting initial combination therapy, as well as how to make this a financial reality based on managed care pharmacy protocols.
This activity is designed for pharmacists, physicians, and other clinicians involved in the treatment of patients with PAH.
Therapeutic selection and management in PAH are intertwined with differential diagnostics, disease classification, and risk stratification. If the incorrect disease classification/risk stratification is made at the incorrect time, inappropriate therapy is often offered, resulting in poor clinical outcomes. Managed care pharmacists must be prepared to update formularies and related dispensing/management protocols to improve outcomes and manage the high costs associated with unnecessary hospitalizations.
Upon completion of this activity, participants will be able to:
•Discuss the role of evidence-based PAH diagnostics and disease classification in therapeutic selection and related formulary decision making.
•List specialty pharmacy best practices and related formulary protocols for improving suboptimal PAH therapeutics and outcomes.
•Describe administrative and/or medical-coding barriers which may impede timely patient access to appropriate PAH therapies.
•Discuss the role of initial PAH combination therapy in reducing overall healthcare utilization costs in PAH patients.
•Evaluate novel and emerging PAH therapies/devices and their role in related PAH utilization management.
•Discuss the role of evidence-based PAH diagnostics and disease classification in therapeutic selection and related formulary decision making.
•List specialty pharmacy best practices and related formulary protocols for improving suboptimal PAH therapeutics and outcomes.
•Describe administrative and/or medical-coding barriers which may impede timely patient access to appropriate PAH therapies.
•Discuss the role of initial PAH combination therapy in reducing overall healthcare utilization costs in PAH patients.
•Evaluate novel and emerging PAH therapies/devices and their role in related PAH utilization management.
Gaylord National Hotel & Convention Center
201 Waterfront Street
Room: National Harbor 4-5
National Harbor, MD 20745 USA
Click here to view location map
Phone: 301-965-4000
201 Waterfront Street
Room: National Harbor 4-5
National Harbor, MD 20745 USA
Click here to view location map
Phone: 301-965-4000
6:30 PM - Registration & Reception
7:00 PM - Dr. Schuller
Disease Classifications & Risk Stratifications
Diagnostic Standards & Recent PAH Guidelines
Suboptimal Therapeutics
Combination Therapy
7:40 PM - Dr. Cannon
Treating PAH in a Managed-care Environment & Dispensing Challenges
Optimizing PAH Care
Cost Savings Strategies
PAH Specialty Formulary & Pharmacy
8:20 PM - 8:30 PM: Q & A
This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., and Bayer HealthCare Pharmaceuticals.
H. Eric Cannon, PharmD, FAMCP
VP, Pharmacy Benefits, SelectHealth
Murray, UT
VP, Pharmacy Benefits, SelectHealth
Murray, UT
Dan Schuller, MD
Chair and Professor, Department of Internal Medicine - The Hospitals of Providence - Transmountain
Texas Tech University Health Sciences Center - Paul L. Foster School of Medicine
El Paso, Texas
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CPE/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CPE/CE activity.
The following financial relationships have been provided:
Eric Cannon, PharmD, FAMCP (Faculty)
No Disclosures
Dan Schuller, MD (Faculty)
Speakers Bureau: Bayer HealthCare Pharmaceuticals, Gilead
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CPE/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CPE/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the live activity and complete the posttest and evaluation, and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate.
Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit. CPE credit will be submitted to CPE Monitor® on the first day of each month.
Inquiries may be directed to ACHL at 773-714-0705, ext. 205.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number: 0018-9999-19-047-L01-P, 1.50 contact hours (1.50 CEU).
